Brian Sarter, MD
Cardiovascular Disease · Newark, DENPI 1851323745
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,261 of the $3,411 with a category attached, or 66.3%. 18 manufacturers reported payments, led by Abbott at 43.7% of the total. Reporting peaked in 2023 at $1,003 and has fallen 73.1% since, to $270 in 2025.
Across 92 payments — averaging $37.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Boston Scientific$827
- Impulse Dynamics (USA) Inc.$336
- Medtronic$289
- Novartis$71
- Amarin Pharma, Inc.$63
- plus $333 from 12 others
Across 19 payments — averaging $1246.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$24K
What the payments were for
- Travel & lodging$1,14934%
- Food & beverage$2,26166%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $1,492 |
| Boston Scientific | 24 | $827 |
| Impulse Dynamics (USA) Inc. | 6 | $336 |
| Medtronic(2 entities) | 8 | $289 |
| Novartis | 5 | $71 |
| Amarin Pharma, Inc. | 4 | $63 |
| Pfizer | 4 | $48 |
| Biosense Webster, Inc. | 1 | $40 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Amgen | 2 | $33 |
| Johnson & Johnson | 2 | $31 |
| Akcea Therapeutics, Inc. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $20 |
| Gilead | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$501
- OPTIMIZER$124
- AMPLATZER AMULET$105
How this compares
$3,411 in reported general payments places this provider in the 55th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 616 | $848,491 |
| XareltoRivaroxaban | 211 | $274,461 |
| EntrestoSacubitril/Valsartan | 132 | $204,092 |
| MultaqDronedarone Hcl | 43 | $88,180 |
| JardianceEmpagliflozin | 24 | $33,281 |
| Flecainide Acetate | 136 | $11,722 |
| Metoprolol Succinate | 580 | $10,156 |
| Amiodarone Hcl | 253 | $9,170 |
| Dofetilide | 11 | $5,484 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $4,902 |
| Atorvastatin Calcium | 366 | $3,914 |
| Ranolazine ErRanolazine | 22 | $2,580 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 59 | $2,516 |
| Lisinopril | 281 | $2,384 |
| Digoxin | 80 | $2,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $848,491616 claims |
| Johnson & JohnsonXarelto | $31 | $274,461211 claims |
| NovartisEntresto | $71 | $204,092132 claims |
| Sanofi-aventis U.S. LLCMultaq | $34 | $88,18043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.